Needham lowered the firm’s price target on Glaukos to $83 from $89 and keeps a Buy rating on the shares. The analyst notes the company’s Q3 revenue beat and believes that the reimbursement dynamics should result in share gains for both iStent inject & infinite in 2024, though the firm’s price target reflects lower peer multiples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GKOS:
- Glaukos raises FY23 revenue view to $307M-$310M, consensus $306.9M
- Glaukos reports Q3 EPS (58c), consensus (55c)
- Piper says WPS update ‘massive blow’ to Sight Sciences, good news for Glaukos
- Needham medtech/diagnostics analysts hold analyst/industry conference call
- Glaukos management to meet with BTIG
